Effect of High-Dose Selenium on Postoperative Organ Dysfunction and Mortality in Cardiac Surgery Patients: The SUSTAIN CSX Randomized Clinical Trial
Christian Stoppe,Bernard McDonald,Patrick Meybohm,Kenneth B Christopher,Stephen Fremes,Richard Whitlock,Siamak Mohammadi,Dimitri Kalavrouziotis,Gunnar Elke,Rolf Rossaint,Philipp Helmer,Kai Zacharowski,Ulf Günther,Matteo Parotto,Bernd Niemann,Andreas Böning,C David Mazer,Philip M Jones,Marion Ferner,Yoan Lamarche,Francois Lamontagne,Oliver J Liakopoulos,Matthew Cameron,Matthias Müller,Alexander Zarbock,Maria Wittmann,Andreas Goetzenich,Erich Kilger,Lutz Schomburg,Andrew G Day,Daren K Heyland,SUSTAIN CSX Study Collaborators,Gregory Hare,Michael Wa Chu,Pierre Voisine,Francois Dagenais,Eric Dumont,Frédérique Jacques,Eric Charbonneau,Jean Perron,Simone Lindau,Roupen Hatzakorizan,Assad Haneya,Georg Trummer,Angela Jareth,Xuran Jiang,Ellen Dresen,Aileen Hill
DOI: https://doi.org/10.1001/jamasurg.2022.6855
2023-03-01
Abstract:Importance: Selenium contributes to antioxidative, anti-inflammatory, and immunomodulatory pathways, which may improve outcomes in patients at high risk of organ dysfunctions after cardiac surgery. Objective: To assess the ability of high-dose intravenous sodium selenite treatment to reduce postoperative organ dysfunction and mortality in cardiac surgery patients. Design, setting, and participants: This multicenter, randomized, double-blind, placebo-controlled trial took place at 23 sites in Germany and Canada from January 2015 to January 2021. Adult cardiac surgery patients with a European System for Cardiac Operative Risk Evaluation II score-predicted mortality of 5% or more or planned combined surgical procedures were randomized. Interventions: Patients were randomly assigned (1:1) by a web-based system to receive either perioperative intravenous high-dose selenium supplementation of 2000 μg/L of sodium selenite prior to cardiopulmonary bypass, 2000 μg/L immediately postoperatively, and 1000 μg/L each day in intensive care for a maximum of 10 days or placebo. Main outcomes and measures: The primary end point was a composite of the numbers of days alive and free from organ dysfunction during the first 30 days following cardiac surgery. Results: A total of 1416 adult cardiac surgery patients were analyzed (mean [SD] age, 68.2 [10.4] years; 1043 [74.8%] male). The median (IQR) predicted 30-day mortality by European System for Cardiac Operative Risk Evaluation II score was 8.7% (5.6%-14.9%), and most patients had combined coronary revascularization and valvular procedures. Selenium did not increase the number of persistent organ dysfunction-free and alive days over the first 30 postoperative days (median [IQR], 29 [28-30] vs 29 [28-30]; P = .45). The 30-day mortality rates were 4.2% in the selenium and 5.0% in the placebo group (odds ratio, 0.82; 95% CI, 0.50-1.36; P = .44). Safety outcomes did not differ between the groups. Conclusions and relevance: In high-risk cardiac surgery patients, perioperative administration of high-dose intravenous sodium selenite did not reduce morbidity or mortality. The present data do not support the routine perioperative use of selenium for patients undergoing cardiac surgery. Trial registration: ClinicalTrials.gov Identifier: NCT02002247.